セフテラム。セフテラムピボキシル
Wikipedia preview
出典(authority):フリー百科事典『ウィキペディア(Wikipedia)』「2019/07/05 09:50:23」(JST)
[Wiki en表示]
Cefteram |
Clinical data |
---|
AHFS/Drugs.com | International Drug Names |
---|
ATC code | |
---|
Legal status |
---|
Legal status |
- In general: ℞ (Prescription only)
|
---|
Identifiers |
---|
IUPAC name
- (6R,7R)-7-([(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-methoxyiminoacetyl]amino)-3-[(5-methyltetrazol-2-yl)methyl]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid
|
CAS Number | |
---|
PubChem CID | |
---|
ChemSpider | |
---|
UNII | |
---|
KEGG | |
---|
ChEMBL | |
---|
Chemical and physical data |
---|
Formula | C16H17N9O5S2 |
---|
Molar mass | 479.49 g/mol g·mol−1 |
---|
3D model (JSmol) | |
---|
SMILES
O=C2N1/C(=C(\CS[C@@H]1[C@@H]2NC(=O)C(=N\OC)\c3nc(sc3)N)Cn4nc(nn4)C)C(=O)O
|
Cefteram (INN) is a third-generation cephalosporin antibiotic.[1]
References
- ^ Yamaguchi, K.; Ohno, A.; Takahashi, S.; Hayashi, M.; Yamanaka, K.; Hirakata, Y.; Mitsuyama, J. (1998). "In vitro antibacterial activities of cefteram and other beta-lactam agents against recent clinical isolates". The Japanese Journal of Antibiotics. 51 (1): 11–25. PMID 9557273.
Antibiotics active on the cell wall and envelope (J01C-J01D) |
---|
Intracellular |
- Inhibit peptidoglycan subunit synthesis and transport: NAM synthesis inhibition (Fosfomycin)
- DADAL/AR inhibitors (Cycloserine)
- bactoprenol inhibitors (Bacitracin)
|
---|
Glycopeptide |
- Inhibit PG chain elongation: Vancomycin# (Oritavancin
- Telavancin)
- Teicoplanin (Dalbavancin)
- Ramoplanin
|
---|
β-lactams/ (inhibit PBP cross-links) | |
---|
Other |
- polymyxins/detergent
- depolarizing
- Hydrolyze NAM-NAG
- Tyrothricin
- Isoniazid#
- Teixobactin
|
---|
- #WHO-EM
- ‡Withdrawn from market
- Clinical trials:
- †Phase III
- §Never to phase III
|
English Journal
- Drug-induced tubulointerstitial nephritis in a retrospective study using spontaneous reporting system database.
- Oyama S, Hosohata K, Inada A, Niinomi I, Mori Y, Yamaguchi Y, Uchida M, Iwanaga K.
- Therapeutics and clinical risk management. 2018 ;14()1599-1604.
- Tubulointerstitial nephritis (TIN) is a problem in clinical settings because drug therapy is the cause in most cases. Patients often present with nonspecific symptoms, which can lead to delays in the diagnosis and treatment of the disease. The purpose of this study was to clarify the rank-order of t
- PMID 30233195
- Preparation of Fine Particles with Improved Solubility Using a Complex Fluidized-Bed Granulator Equipped with a Particle-Sizing Mechanism.
- Hosaka S, Okamura Y, Tokunaga Y.
- Chemical & pharmaceutical bulletin. 2016 ;64(6)644-9.
- A new type of fluidized-bed granulator equipped with a particle-sizing mechanism was used for the preparation of fine particles that improved the solubility of a poorly water-soluble drug substance. Cefteram pivoxyl (CEF) was selected as a model drug substance, and its solution with a hydrophilic po
- PMID 27250799
- New sensitization to house dust mites in cefteram-induced occupational asthma: a case report.
- Jin HJ, Kim JE, Kim JH, Ye YM, Park HS.
- Allergy, asthma & immunology research. 2011 Apr;3(2)132-4.
- Occupational asthma (OA) can improve after cessation of exposure; however, some patients suffer from persistence or aggravation of their asthmatic symptoms. Here we report a case of a new sensitization to house dust mites during the follow-up period in a 37-year-old female patient with OA induced by
- PMID 21461254
Japanese Journal
- Clinical Efficacy Assessment of Cefteram Pivoxil Using Clinical Scoring Systems in Children with Acute Rhinosinusitis
- Inagawa Shuntaro,Baku Masayo,Shimizu Takahiro,Hoshino Tetsuro,Nonogaki Eba,Hirayama Hajime,Uchida Yasue,Tanigawa Toru,Ogawa Tetsuya,Ueda Hiromi
- 耳鼻咽喉科臨床 補冊 141(0), 54-55, 2015
- … In the present study, we assessed the efficacy of cefteram pivoxil in children with moderate or more severe acute rhinosinusitis. … Cefteram pivoxil administered at 18 mg/kg/day showed better efficacy and rapid onset of action. …
- NAID 130005077945
- 薬物 小児急性鼻副鼻腔炎のスコアリングシステムによるセフテラムピボキシル(CFTM-PI)の有効性評価
- 小児急性鼻副鼻腔炎のスコアリングシステムによるセフテラムピボキシル(CFTM-PI)の有効性評価
- 稲川 俊太郎,麦 雅代,清水 崇博,星野 哲朗,野々垣 絵羽,平山 肇,内田 育恵,谷川 徹, 小川徹也,植田 広海
- 耳鼻咽喉科臨床 107(9), 735-741, 2014
- … In the present study, we assessed the efficacy of cefteram pivoxil in children with moderate or more severe acute rhinosinusitis. … Cefteram pivoxil administered at 18 mg/kg/day showed better efficacy and rapid onset of action. …
- NAID 130004685617
Related Links
- 本サイトの提供情報は、「治療の参考」として提供するものであり、 実際の使用に当たっては、「添付文書」等の各製薬会社が提供する情報に従ってご使用ください。
- Cefteram Pivoxil is the pivalate ester prodrug of cefteram, a semi-synthetic, broad-spectrum, third-generation cephalosporin with antibacterial activity. ... Cefteram Pivoxil is the pivalate ester prodrug of cefteram, a semi-synthetic, broad ...
- Cefteram Pivoxil Ceftibuten Ceftizoxime Ceftriaxone Cefuroxime Axetil Chloramphenicol Cinoxacin Ciprofloxacin Clarithromycin Clindamycin Dibekacin Doripenem Doxycycline Erythromycin Faropenem Flomoxef Fosfomycin ...
Related Pictures
★リンクテーブル★
[★]
- 英
- cefteram
- 化
- セフテラムピボキシル cefteram pivoxil CFTM-PI
- 商
- セトラート、ソマトロン、テラセフロン、テラミロン、トミロン、ボキシロン
- 関
- 抗菌薬
第三世代セフェム系抗生物質
[★]
セフテラム セフテラムピボキシル cefteram pivoxil